GlassScriptPhysician profile
Mark B Saltzman
NPI 1902898919
$10,460.17
in general payments reported to CMS, 2019-2025
44 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $648 · 2021: $701 · 2022: $1,741 · 2023: $2,410 · 2024: $1,896 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,755.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,636.17 | 2019-2025 | Jot Dx, Confirm Rx, Gallant |
| Amgen INC. | $1,052.39 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,025.00 | 2019-2025 | |
| Pfizer INC. | $942.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $865.94 | 2019-2025 | Jardiance |
| Philips North America LLC | $614.16 | 2020-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| E.R. Squibb & Sons, L.L.C. | $557.26 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $335.19 | 2019-2025 | Farxiga, Wainua |
| Atricure, INC. | $310.97 | 2019-2023 | |
| Boston Scientific Corporation | $309.75 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, General - Structural Heart |
| Janssen Pharmaceuticals, INC | $306.75 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $290.80 | 2021-2023 | Verquvo |
| Astellas Pharma US INC | $251.24 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $212.08 | 2019-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.83 | 2019-2025 | Lifevest |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $172.15 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $122.47 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $122.30 | 2023-2025 | |
| Novo Nordisk INC | $105.38 | 2025 | Ozempic |
| Kowa Pharmaceuticals America, INC. | $88.96 | 2019-2023 | Livalo |
| Esperion Therapeutics, INC. | $83.79 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $83.48 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $74.90 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $66.68 | 2023-2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $62.51 | 2019 | |
| Biosense Webster, INC. | $56.73 | 2022 | |
| Edwards Lifesciences Corporation | $49.82 | 2024 | |
| Medtronic, INC. | $48.46 | 2021-2023 | Micra |
| Bridgebio Pharma, INC. | $47.72 | 2025 | Attruby |
| Cleerly, INC. | $46.26 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic Vascular, INC. | $44.95 | 2019 | |
| Chiesi USA, INC. | $33.45 | 2020-2022 | |
| Abiomed | $30.95 | 2024 | Impella |
| Cardiva Medical, INC. | $29.08 | 2022 | |
| Heartflow, INC. | $26.25 | 2024 | |
| Agepha Pharma Fz LLC | $24.66 | 2024 | Lodoco |
| Lexicon Pharmaceuticals, INC. | $24.38 | 2023 | Inpefa |
| Cvrx, INC. | $20.06 | 2024 | Barostim Neo System |
| Surmodics, INC. | $19.48 | 2025 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight |
| Lilly USA, LLC | $18.33 | 2025 | Zepbound, Mounjaro |
| Akcea Therapeutics, INC. | $16.36 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.15 | 2019 | |
| Gilead Sciences, INC. | $14.00 | 2019 | |
| Shockwave Medical, INC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Saltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.